Skip to content
Back to search results

HAQ Disability Index

Introduced by
James Fries and colleagues at Stanford University
Year
1980
Type
Functional disability measurement for arthritis and chronic disease
Family
Functional assessment
Font size

What does it do?

The Health Assessment Questionnaire Disability Index (HAQ-DI) is a 20-item self-report measure of functional disability developed by Fries and colleagues at Stanford University in 1980.

Originally designed for rheumatoid arthritis, the HAQ-DI has become the gold-standard functional assessment instrument across diverse rheumatic diseases and chronic conditions.

The intuition behind the method

The HAQ-DI measures the impact of disease on daily living by assessing ability to perform routine physical activities across eight domains: dressing, rising, eating, walking, hygiene, reach, grip, and common activities. Rather than summing all items equally, the HAQ-DI uses a sophisticated scoring system where patients report assistive devices and help needed, reflecting a continuum from independence to disability. This detailed approach makes it clinically meaningful for both research and patient care.

History

The Health Assessment Questionnaire was developed by James Fries at Stanford University in the late 1970s and formally published in 1980. It emerged from earlier work on Multidimensional Health Status Measures and was specifically tailored to rheumatoid arthritis assessment. The Disability Index (HAQ-DI) became the most widely adopted component of the larger HAQ instrument. Subsequent versions expanded the HAQ into a multidimensional questionnaire (MDHAQ), and the HAQ-DI remains the functional disability component across these variations. The instrument has been translated into 50+ languages and is used in thousands of rheumatology trials worldwide.

When to use it

The HAQ-DI is the preferred instrument for assessing functional outcomes in rheumatic disease trials and clinical practice monitoring. It is appropriate for patients aged 5+ years across all arthropathies (rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, etc.). The HAQ-DI is less suitable for acute injury or post-surgical assessment; condition-specific functional scales may be preferable in those contexts.

Limitations and considerations

  • Originally designed for arthritis; extrapolation to non-rheumatic conditions may require validation
  • Predominantly assesses physical function; does not capture cognitive or emotional disability
  • Ceiling effects in mild disease; limited discrimination among high-functioning patients
  • Assistive device/help factors may not apply uniformly across cultural contexts and healthcare systems

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Extensively validated across rheumatic diseases with strong correlation to other functional and clinical measures
  • Sensitive to change in clinical trials; detects meaningful functional improvement and decline
  • Simple, intuitive scoring reflects practical disability relevant to patients' lived experience
  • Brief administration time (5 minutes) and self-completion enable use in busy clinical settings
  • Strong predictive validity for health outcomes, joint damage progression, and mortality in arthritis

Applications

  • Rheumatoid arthritis trials: standard outcome measure in regulatory submissions and pharmaceutical clinical trials
  • Disease activity assessment: monitoring functional trajectory alongside inflammatory markers in clinical practice
  • Prognostic prediction: baseline HAQ-DI predicts joint damage progression, healthcare utilization, and mortality
  • Comparative effectiveness: measuring functional impact across different drug classes and biologics
  • Longitudinal cohort studies: decades-long tracking of disability trends in arthropathies

How it works

How it works

1

The HAQ-DI consists of 20 items organized into 8 functional categories. Respondents rate difficulty (0 = without difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do) on a 4-point Likert scale. They also indicate whether they use assistive devices or need help from another person. Administration takes 5 minutes.

2

For each of the 8 categories, the highest difficulty rating is selected. If the respondent reports using an assistive device or needing help, the score is set to 2 or higher respectively. The overall HAQ-DI score is the average of the 8 category scores, ranging from 0 (no disability) to 3 (severe disability). An alternative dichotomous score (0 = minimal disability, 1 = any disability) is used in some research.

3

HAQ-DI scores range 0–3; higher scores indicate greater disability. Clinical thresholds vary: 0 = no disability or minimal disability, 0.01–0.5 = mild to moderate disability, 0.51–1.5 = moderate to severe disability, >1.5 = severe disability. Changes of ≥0.22 are considered clinically significant in rheumatoid arthritis trials.

Common pitfalls

  • Failing to account for the assistive device/help weighting system in scoring; manual calculation without this algorithm yields incorrect scores
  • Applying arthritis-based HAQ-DI cutoffs to non-rheumatic populations without validation
  • Interpreting HAQ-DI as a quality-of-life measure; it measures functional disability, not life satisfaction
  • Using HAQ-DI in acute settings; it reflects chronic baseline function better than acute injury limitation

Frequently asked questions

What is the significance of the assistive device and help factors in HAQ-DI scoring?

The use of assistive devices or needing help from another person reflects disease severity beyond difficulty rating alone. A patient unable to climb stairs even with a cane (score 3 with device) has greater functional impairment than one with difficulty but independence. This weighting makes HAQ-DI more sensitive to real-world disability.

What does a HAQ-DI score of 0.75 indicate?

A score of 0.75 indicates moderate to moderately severe disability, suggesting the patient has significant limitations in routine activities. Contextually, this reflects meaningful disease burden; improvement to 0.5 or below would represent clinically important response to treatment in arthritis trials.

Can HAQ-DI be used in conditions other than rheumatoid arthritis?

The HAQ-DI has been used in systemic lupus erythematosus, osteoarthritis, and other conditions with varying degrees of validation. When using it outside arthritis, ensure the conceptual basis (physical functional limitation) aligns with your condition and validate thresholds against relevant outcome measures.

How often should HAQ-DI be assessed in clinical monitoring?

In clinical practice, HAQ-DI is typically assessed at baseline and at defined follow-up intervals (e.g., quarterly or semi-annually) aligned with disease activity monitoring. In trials, assessment frequency depends on expected rate of functional change; monthly in intensive interventions, quarterly in typical drug trials.

Related methods

Sources

  1. Bruce, B., & Fries, J. F. (1989). The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. Journal of Rheumatology, 16(8), 1055–1064.

    Open publication reference
    Copied.
  2. Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980). Measurement of patient outcome in arthritis. Arthritis & Rheumatism, 23(2), 137–145.

    Open DOI reference
    Copied.
  3. Pincus, T., Swearingen, C., & Wolfe, F. (2011). Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological well-being. Seminars in Arthritis and Rheumatism, 30(2), 10–17.

    Open publication reference
    Copied.